These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Activation of T lymphocytes for the adoptive immunotherapy of cancer. Sussman JJ; Shu S; Sondak VK; Chang AE Ann Surg Oncol; 1994 Jul; 1(4):296-306. PubMed ID: 7850528 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells. Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722 [TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy of tumors: from the first experimental studies to the recent clinical applications. I. Passive immunotherapy]. Burrai I; Di Lallo A Minerva Med; 1991 Sep; 82(9):519-28. PubMed ID: 1944999 [TBL] [Abstract][Full Text] [Related]
5. Adoptive cellular therapy of malignancy. Chang AE; Geiger JD; Sondak VK; Shu S Arch Surg; 1993 Nov; 128(11):1281-90. PubMed ID: 8239992 [TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860 [TBL] [Abstract][Full Text] [Related]
7. Interleukin 2 in cancer therapy. Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501 [TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy. Ballen K; Stewart FM Curr Opin Oncol; 1997 Nov; 9(6):579-83. PubMed ID: 9370080 [TBL] [Abstract][Full Text] [Related]
9. Cellular immunotherapy for malignant gliomas. Lin Y; Okada H Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205 [TBL] [Abstract][Full Text] [Related]
11. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Rosenberg SA Ann Surg; 1988 Aug; 208(2):121-35. PubMed ID: 3041925 [TBL] [Abstract][Full Text] [Related]
12. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Inoue M; Plautz GE; Shu S Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987 [TBL] [Abstract][Full Text] [Related]
13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
14. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248 [TBL] [Abstract][Full Text] [Related]
15. [Cellular immunotherapy of cancer]. Kawakami Y Rinsho Ketsueki; 2003 Jun; 44(6):358-67. PubMed ID: 12884813 [No Abstract] [Full Text] [Related]
16. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Rosenberg SA Annu Rev Med; 1996; 47():481-91. PubMed ID: 8712798 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells. Rodolfo M; Salvi C; Bassi C; Rovetta G; Melani C; Colombo MP; Parmiani G Nat Immun Cell Growth Regul; 1991; 10(6):308-19. PubMed ID: 1787836 [TBL] [Abstract][Full Text] [Related]